Immunological, Mental and Physical After-effects of COVID-19 infection

Immunological, Mental and Physical After-effects of COVID-19 infection - IMPACD-2 study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55044

Enrollment

450

Registered

2020-08-17

Start date

2020-09-22

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19 infection with SARSCoV2

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: all patients who visited the postCOVID outpatient clinic in the OLVG 3 months after their COVID19 infection

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
recovery of quality of life based on the results of questionnaires after COVID19 infection	—

Secondary

Measure	Time frame
1. occurrence of new infections with SARSCoV2 within year after admission with COVID19 infection, based on self-report, confirmed with (patient approved) requested information about the confirmation of that infection in another laboratory 2.outcomes of lung function studies in patients who still had an impaired lung function test after 3 months and who are being followed up at the outpatient clinic for lung diseases at 6, 12 and 18-24 months after COVID19 infection 3.occurrence of death within a year after COVID19 infection and record of cause of death (retrieved via GP, with prior patient consent) 4.height of concentration of antibodies against SARSCoV2 at 6 and 12 months after admission with COVID19 infection	—

Measure

Time frame

1. occurrence of new infections with SARSCoV2 within year after admission with COVID19 infection, based on self-report, confirmed with (patient approved) requested information about the confirmation of that infection in another laboratory 2.outcomes of lung function studies in patients who still had an impaired lung function test after 3 months and who are being followed up at the outpatient clinic for lung diseases at 6, 12 and 18-24 months after COVID19 infection 3.occurrence of death within a year after COVID19 infection and record of cause of death (retrieved via GP, with prior patient consent) 4.height of concentration of antibodies against SARSCoV2 at 6 and 12 months after admission with COVID19 infection

—

Countries

Netherlands

Outcome results